Priya Godara and Dhaneswar Prusty
The development of parasite resistance to primary antimalarial drugs has caused a significant number of fatalities in malaria-affected countries, with drug target mutations being the sole reason. As a potential solution, the development of multitargeting drugs has gained attention. Studies have shown that the probability of multiple target mutations is low because it would significantly impact the parasite's *Corresponding Author: Dr Dhaneswar Prusty; Email: dhaneswarprusty@curaj.ac.in Cite this article as: fitness. Furthermore, multitargeting drugs have the potential to be effective with reduced dosages, increased efficiency, and improved safety profiles. Among the viable targets for malaria drug development, kinases, a class of enzymes that play a critical role in various stages of the parasite's life cycle, are highly promising. Therefore an integrative approach combining computational methods, biochemical target-specific inhibition assays, and phenotypic screening may be an effective strategy for developing antimalarial compounds targeting multiple kinases.
Priya Godara and Dhaneswar Prusty, 2023. A Rational Approach for Designing Multitargeting Antimalarial Compounds Targeting Plasmodium falciparum Kinases to Effectively Combat Rapidly Emerging Drug Resistance. Journal of Medical Arthropodology & Public Health 3(1): 15–22.